Welcome to our dedicated page for Pasithea Therapeutics news (Ticker: ktta), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pasithea Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pasithea Therapeutics's position in the market.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) announced a collaboration with Evotec, a leading drug development company, to advance its initial drug candidate targeting psychiatric disorders. This partnership marks the start of a new chemical entity development program focused on neuroinflammatory pathways linked to depression and schizophrenia. The collaboration aims to leverage Evotec's expertise to expedite the drug's progression toward clinical trials. The company's strategic focus is on developing innovative treatments for psychiatric conditions and establishing psychiatric clinics in the UK and US.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) has announced that CEO Dr. Tiago Reis Marques will present at the Benzinga Healthcare Small Cap Conference on September 30, 2021, at 10:10 AM ET. The live presentation will be available via webcast and archived for 30 days on the company's website. Pasithea focuses on developing treatments for psychiatric and neurological disorders, targeting pathophysiology to improve efficacy and tolerability compared to conventional therapies. The company also provides business support services for anti-depression clinics in the UK and the US.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) has successfully closed its initial public offering of 4,800,000 units at a price of $5.00 per unit, generating approximately $24.0 million in gross proceeds. Each unit consists of one share of common stock and one warrant for an additional share. The company's stock and warrants began trading on Nasdaq on September 15, 2021. The offering aims to support the company’s focus on discovering new treatments for psychiatric and neurological disorders.